MorphoSys AG (MOR) Given a €68.00 Price Target by Berenberg Bank Analysts
Several other research analysts have also commented on MOR. Goldman Sachs Group, Inc. (The) set a €55.00 ($65.48) price target on shares of MorphoSys AG and gave the company a neutral rating in a report on Friday, August 4th. Deutsche Bank AG set a €90.00 ($107.14) price target on shares of MorphoSys AG and gave the company a buy rating in a report on Monday, August 7th. Commerzbank Ag set a €76.00 ($90.48) price target on shares of MorphoSys AG and gave the company a buy rating in a report on Friday, July 14th. J P Morgan Chase & Co restated a neutral rating on shares of MorphoSys AG in a report on Monday, July 17th. Finally, Independent Research GmbH set a €77.00 ($91.67) price target on shares of MorphoSys AG and gave the company a buy rating in a report on Monday, August 7th. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The stock presently has an average rating of Buy and a consensus price target of €70.38 ($83.78).
MorphoSys AG (ETR:MOR) opened at 68.399 on Tuesday. The company has a 50 day moving average of €60.74 and a 200-day moving average of €59.75. The firm’s market cap is €1.98 billion. MorphoSys AG has a one year low of €35.72 and a one year high of €70.90.
MorphoSys AG Company Profile
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.
Receive News & Ratings for MorphoSys AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys AG and related companies with Analyst Ratings Network's FREE daily email newsletter.